Rxsight Inc
NASDAQ:RXST
Rxsight Inc
In the dynamic realm of ophthalmology, RxSight Inc. has carved a niche as a pioneering force in enhancing vision outcomes for cataract patients. At the heart of the company’s innovation is its Light Adjustable Lens (LAL) system. Traditional intraocular lenses (IOLs), once implanted, lock patients into a certain prescription, accepting only minimal adjustments. RxSight, with its groundbreaking technology, offers a solution that breaks this convention. Post-cataract surgery, the LAL allows ophthalmologists to precisely adjust the lens prescription using UV light, often yielding better visual acuity tailored to patient needs. This transformative approach turns the one-size-fits-all model of vision correction into a personalized patient experience, promising a brighter, clearer outlook on life.
Commercially, RxSight operates within the medical device industry, focusing on capturing a significant share of the cataract surgery market—one of the most frequent surgeries performed worldwide. The company earns revenue primarily through the sale of its LAL system to eye care professionals and clinics. This business model is akin to a razor-and-blade approach; besides the initial sale of the adjustable lenses, RxSight garners continuous revenue from associated products and services, such as the light delivery device and follow-up adjustments required post-surgery. By addressing a substantial unmet need with a recurring revenue stream, RxSight strategically positions itself for growth within the burgeoning biotech sector, all while setting new benchmarks for patient satisfaction in eye care.
In the dynamic realm of ophthalmology, RxSight Inc. has carved a niche as a pioneering force in enhancing vision outcomes for cataract patients. At the heart of the company’s innovation is its Light Adjustable Lens (LAL) system. Traditional intraocular lenses (IOLs), once implanted, lock patients into a certain prescription, accepting only minimal adjustments. RxSight, with its groundbreaking technology, offers a solution that breaks this convention. Post-cataract surgery, the LAL allows ophthalmologists to precisely adjust the lens prescription using UV light, often yielding better visual acuity tailored to patient needs. This transformative approach turns the one-size-fits-all model of vision correction into a personalized patient experience, promising a brighter, clearer outlook on life.
Commercially, RxSight operates within the medical device industry, focusing on capturing a significant share of the cataract surgery market—one of the most frequent surgeries performed worldwide. The company earns revenue primarily through the sale of its LAL system to eye care professionals and clinics. This business model is akin to a razor-and-blade approach; besides the initial sale of the adjustable lenses, RxSight garners continuous revenue from associated products and services, such as the light delivery device and follow-up adjustments required post-surgery. By addressing a substantial unmet need with a recurring revenue stream, RxSight strategically positions itself for growth within the burgeoning biotech sector, all while setting new benchmarks for patient satisfaction in eye care.
Revenue: Q4 2025 sales were $32.6 million, down 19% year-over-year due to lower LDD sales; full year 2025 sales reached $134.5 million, up 4% year-over-year.
Guidance: 2026 revenue is expected to be $120–135 million, implying a year-over-year decline of about 5% at the midpoint, mainly from lower LDD placements.
Gross Margin: Q4 2025 gross margin rose to 77.5%, but 2026 guidance is down to 70–72% due to higher cost inventory and mix headwinds.
Profitability: Q4 net loss was $9.2 million ($0.22 per share); full year 2025 net loss was $38.9 million ($0.95 per share).
Installed Base: The LDD installed base grew 17% year-over-year to 1,134 units by end of 2025.
Execution Focus: Management stressed disciplined capital placement, boosting utilization in existing accounts, and a methodical international rollout.
Innovation: Continued strong clinical results and new product approvals, with further submissions planned over the next 18 months.
Market Trends: Premium IOL market showing signs of recovery; RxSight sees itself well positioned despite competitive launches in 2025.
